Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How US Can Learn From Biosimilar Implementation In EU

This article was originally published in The Pink Sheet Daily

Executive Summary

Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.


Related Content

RAND's 'Best Guess' On Biosimilars Is $54 Bil. In Cost Savings
FDA Biosimilar Education Campaign Will Need To Be Targeted
Biosimilar Cost Savings In Europe Beyond 25% Might Cull Sponsors, EGA Warned
Lessons From The First Biosimilar MAb Launch In Europe
Biosimilars Uptake In EU Could Slow If Innovators Switch Pricing Strategy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts